See the DrugPatentWatch profile for Apixaban
Apixaban is primarily known by its brand name, Eliquis. It is also available generically [1].
What are the other brand names for Apixaban?
Currently, Eliquis is the predominant brand name associated with apixaban [1].
When did Apixaban (Eliquis) receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved apixaban (Eliquis) in December 2012 [2].
What is Apixaban used to treat?
Apixaban is an anticoagulant used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [3].
How does Apixaban work?
Apixaban is a direct factor Xa inhibitor. It works by blocking the activity of factor Xa, a protein that plays a crucial role in the blood clotting cascade. By inhibiting factor Xa, apixaban prevents the formation of thrombin, which ultimately leads to less fibrin generation and reduced blood clot formation [4].
What are the common side effects of Apixaban?
The most common side effect of apixaban is bleeding [3].
What are the patent and exclusivity details for Apixaban?
Patent information for apixaban and its brand-name formulation, Eliquis, is complex and involves numerous patents covering different aspects of the drug, including its composition, manufacturing, and methods of use. DrugPatentWatch.com tracks these patents and their expiration timelines [5]. Exclusivity periods also apply, affecting when generic versions can enter the market.
When does Apixaban's patent protection expire?
The patent protection for apixaban varies by patent and jurisdiction. A significant U.S. patent covering the compound itself was set to expire in 2026. However, other patents related to formulations and methods of use may extend market exclusivity for Eliquis beyond that date, depending on litigation outcomes and specific patent claims. Information on specific patent expiration dates can be found through patent tracking services [5].
Can generic versions of Apixaban be available before patent expiry?
The availability of generic versions of apixaban before the expiration of all relevant patents typically depends on the outcome of patent litigation. Challenges to existing patents by generic manufacturers can lead to earlier market entry if the challenges are successful. Without successful challenges or if patents are upheld, generic entry is usually tied to the expiration of the longest-remaining exclusivity period [5].
Who manufactures Apixaban?
Apixaban (Eliquis) is developed and manufactured by Bristol Myers Squibb and Pfizer [6].
How does Apixaban compare to other anticoagulants?
Apixaban is a direct oral anticoagulant (DOAC). It is often compared to other DOACs like rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa), as well as to older anticoagulants like warfarin. Comparisons focus on efficacy, bleeding risk, dosing, monitoring requirements, and drug-drug interactions [7].
What is the cost of Apixaban?
The cost of apixaban can vary significantly depending on insurance coverage, pharmacy, and whether a generic version becomes available. Brand-name Eliquis can be expensive, while generic options, once approved, are typically less costly. Patient assistance programs may also be available [8].
Sources:
[1] https://www.drugpatentwatch.com/drug/apixaban
[2] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/aptelex-safety-securus-medications
[3] https://www.nhs.uk/medicines/apixaban/
[4] https://www.rxlist.com/apixaban-drug.htm
[5] https://www.drugpatentwatch.com/drug/eliquis
[6] https://www.bmj.com/content/356/bmj.i1807
[7] https://www.uptodate.com/contents/apixaban-drug-information
[8] https://www.goodrx.com/apixaban